| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2875068 | The Annals of Thoracic Surgery | 2013 | 9 Pages |
Abstract
Short-course rapamycin treatment protects against airway epithelium loss and subsequent development of BO in a murine model. Because of its immunosuppressive and antifibrotic effects, rapamycin may prove to be the ideal medication to prevent chronic rejection and BO in patients undergoing lung transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jacob R. MD, Yunge MD, PhD, David A. BS, Damien J. MD, MSc, Irving L. MD, Christine L. MD, MBA,